Bharat Biotech reduces Covaxin's price from Rs600 to Rs400 per dose for Indian states
"We wish to be transparent in our approach to pricing which was determined by internally funded product development, several operationally intensive BSL-3 manufacturing facilities (the first of its kind on our country) and clinical trials," the company said
Bharat Biotech on Thursday announced it will charge state governments Rs400 for a dose of Covaxin, instead of Rs600, as earlier announced. The move comes a day after Pune's Serum Institute of India brought down the price from Rs400 to Rs300 for state governments.
Expressing deep concerns over the present pandemic situation of the country, Bharat Biotech said, "We wish to be transparent in our approach to pricing which was determined by internally funded product development, several operationally intensive BSL-3 manufacturing facilities (the first of its kind on our country) and clinical trials."
"Recognising the enormous challenges to the public health care system, we have made Covaxin available to state governments at a price of Rs400 per dose," the Hyderabad-based company said.
Keep updated, follow The Business Standard's Google news channel
The third phase of vaccination against Covid-19 will begin from May 1 in which people between the age group of 18 and 44 years will be considered eligible to get vaccine doses. As this is an extension of the ongoing vaccination drive of the country, the Centre has allowed state governments and private hospitals to procure vaccines separately from the makers.
